Close Menu

NEW YORK (GenomeWeb) – Bio-Rad reported after the close of the market Tuesday that its first quarter revenues increased 10 percent year over year driven by growth in both its Life Science and Clinical Diagnostics businesses.

For the three months ended March 31, Bio-Rad tallied net sales of $551.5 million compared to $500.1 million in Q1 2017, beating analysts' consensus estimate of $527.2 million. On a currency-neutral basis, Q1 sales increased 4.5 percent year over year, the company said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.

The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.

Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.

In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.

May
22
Sponsored by
Stilla

This webinar will outline the entire liquid biopsy workflow from cell-free DNA isolation to mutation detection by Crystal Digital PCR with the Naica System from Stilla Technologies.